ResMed Inc. 10-Q Summary: Quarter Ended September 30, 2006
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2006 for ResMed Inc., a leading developer and manufacturer of medical equipment for sleep-disordered breathing and respiratory disorders. The company operates globally with manufacturing in Australia, Germany, France, and the U.S. The financial statements are unaudited and reflect a two-for-one stock split declared in August 2005.
Key Financial Metrics
| Metric (in thousands, except per share) | Q3 2006 | Q3 2005 |
|---|---|---|
| Net Revenues | $163,605 | $127,127 |
| Gross Profit | $101,296 | $80,119 |
| Gross Margin | 62.0% | 63.0% |
| Operating Income | $35,316 | $24,513 |
| Net Income | $24,999 | $16,442 |
| Diluted EPS | $0.32 | $0.23 |
| Cash from Operations | $26,132 | $15,940 |
| Cash & Equivalents (End of Period) | $201,155 | $129,729 |
| Total Debt (Current + Long-term) | $120,309 | $121,081 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 29% year-over-year, driven by higher unit sales of flow generators, masks, and accessories. North and Latin America revenue grew 34%, while international markets grew 23% (19% organic growth excluding currency impacts).
- Profitability: Net income rose 52% to $25.0 million. Diluted EPS increased from $0.23 to $0.32.
- Margin Compression: Gross margin decreased slightly from 63% to 62%, primarily due to a higher sales mix in North and Latin America, which typically carry lower margins than international sales.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 20% to $53.4 million due to personnel increases and infrastructure investments. R&D expenses increased 29% to $10.9 million.
- Restructuring: No restructuring expenses were incurred in Q3 2006, compared to $1.0 million in the prior year quarter.
Outlook, Risks, and Management Commentary
- Guidance: Management expects SG&A to remain in the range of 31% to 34% of net revenue and R&D to remain in the range of 6% to 7%.
- Capital Expenditures: CapEx was $28.1 million, primarily for new R&D and office facilities in Sydney and computer hardware. The company is assessing a $9.6 million expansion of its warehouse and manufacturing facility.
- Liquidity: The company maintains strong liquidity with $221.2 million in cash and marketable securities. It has a $75 million undrawn revolving credit facility and a syndicated facility with HSBC (Tranche A: $61.2M outstanding; Tranche C: $58.3M outstanding).
- Risks: Key risks include foreign currency exchange rate fluctuations (hedged via options), potential changes in tax laws (specifically regarding FIN 48 adoption in 2007), and the outcome of ongoing legal proceedings regarding patent inventorship and tax audits in Germany.
- Acquisitions: The company paid a $0.3 million milestone payment related to the Pulmomed acquisition.
Investor Verification Checklist
- Geographic Mix Impact: Verify the sustainability of revenue growth given the shift toward lower-margin North American sales.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically the total debt to EBITDA ratio and fixed charge coverage ratio.
- Inventory Levels: Monitor inventory growth ($123.0M) relative to sales to ensure no obsolescence risks, though management cites improved working capital management.
- Foreign Currency Exposure: Assess the effectiveness of the hedging program against the Australian Dollar and Euro given the company's significant international operations.
- Legal Contingencies: Review updates on the German tax audit and the patent inventorship litigation involving former MAP contractors.